

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) Active-ingredient-containing formulation ~~with~~comprising a plurality of active-ingredient-containing phases ~~which is characterized in that~~wherein the formulation ~~has~~comprises a first innermost finely divided phase (I) which consists of active ingredient or active ingredient solution, ~~of which preferably~~wherein at least some phase particles optionally are surrounded with a barrier mantle (M), and that the formulation has a second, middle phase (II) which serves as dispersant for the first, inner phase (I) and in which active ingredient may likewise be dissolved, and ~~that the formulation has~~ a third outer phase (III) which serves as dispersant for the second middle phase and in which active ingredient may in turn be present in dissolved form and/or in the form of solid particles, which ~~again may be~~optionally are surrounded with a barrier mantle.
2. (Currently Amended) Formulation according to Claim 1, ~~characterized in that~~wherein the intermediate phase (II) ~~when applying the formulation to a surface~~ acts as mechanical stabilization of the innermost phase (I) ~~and thus brings about a longer service life of the dispersion of the innermost phase (I).~~
3. (Currently Amended) Formulation according to Claim 1 ~~or 2~~, ~~characterized in that~~wherein a plurality of biologically effective active ingredients in the various phases are combined in varying concentrations and with a release rate which is controlled in each case in a single formulation.

4. (Currently Amended) Formulation according to ~~one of Claims 1 to 3~~, characterized in ~~that~~wherein the formulation limits the release of the active ingredient from the innermost phase by choosing a suitable solvent for the outer phase.
5. (Currently Amended) Formulation according to ~~one of Claims 1 to 4~~, characterized in ~~that~~wherein the barrier mantle in the various phases is a microcapsule.
6. (Currently Amended) Formulation according to Claim 5, characterized in ~~that~~wherein the microcapsule of the barrier mantle is based on a polymer.
7. (Currently Amended) Formulation according to ~~one of Claims 1 to 6~~, characterized in ~~that~~wherein the outer third phase is an oil phase, ~~preferably of silicone oil or castor oil~~.
8. (Currently Amended) Formulation according to ~~one of Claims 1 to 7~~, characterized in ~~that~~wherein the inner second phase is based on gelatin.
9. (Currently Amended) ~~Use of the~~A method for the controlled release of an active ingredient in a patient comprising administering to said patient a formulation according to ~~one of Claim 1~~.